NEW YORK, Nov. 5, 2015 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Oncolytics Biotech Inc. (TSX: ONC; OTCQX: ONCY), a Canada-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, has qualified to trade on the OTCQX® Best Market. Oncolytics previously traded on the NASDAQ Capital Market.
Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
Oncolytics begins trading today on OTCQX under the symbol "ONCY." U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com.
"Oncolytics is on the cutting edge of cancer innovation, developing new therapies for the treatment of a wide range of cancers," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "We are proud to welcome this dynamic company to the OTCQX Best Market."
"We are proud to join the impressive and rapidly growing list of international companies whose shares trade on OTCQX," said Dr. Brad Thompson, President and CEO of Oncolytics. "The OTCQX platform offers U.S. investors convenient trading in Oncolytics' shares in a market that is both efficient and transparent."
Dorsey & Whitney LLP serves as Oncolytics' Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. securities laws.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN®, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into markets to inform investors of opportunities and risks: the OTCQX® Best Market; the OTCQB® Venture Market; and the OTC Pink® Open Market. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial markets, visit www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
Media Contact:
Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, saskia@otcmarkets.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/otc-markets-group-welcomes-oncolytics-biotech-inc-to-otcqx-300172894.html
SOURCE OTC Markets Group Inc.